Schroder Investment Management Group Increases Stock Position in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Schroder Investment Management Group lifted its holdings in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 145.1% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 2,229,786 shares of the company’s stock after buying an additional 1,320,076 shares during the period. Schroder Investment Management Group owned about 0.20% of Teva Pharmaceutical Industries worth $49,769,000 at the end of the most recent reporting period.

Other hedge funds have also modified their holdings of the company. DnB Asset Management AS lifted its stake in shares of Teva Pharmaceutical Industries by 13.3% in the fourth quarter. DnB Asset Management AS now owns 184,940 shares of the company’s stock valued at $4,076,000 after purchasing an additional 21,727 shares during the period. Orion Portfolio Solutions LLC lifted its position in shares of Teva Pharmaceutical Industries by 11.9% during the 4th quarter. Orion Portfolio Solutions LLC now owns 12,302 shares of the company’s stock valued at $271,000 after acquiring an additional 1,310 shares during the period. Pictet Asset Management Holding SA boosted its stake in shares of Teva Pharmaceutical Industries by 9.7% during the 4th quarter. Pictet Asset Management Holding SA now owns 598,487 shares of the company’s stock worth $13,191,000 after acquiring an additional 52,938 shares in the last quarter. Norges Bank acquired a new stake in shares of Teva Pharmaceutical Industries in the 4th quarter worth approximately $38,550,000. Finally, Blair William & Co. IL increased its stake in Teva Pharmaceutical Industries by 9.4% in the 4th quarter. Blair William & Co. IL now owns 11,232 shares of the company’s stock valued at $248,000 after purchasing an additional 963 shares in the last quarter. 54.05% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

TEVA has been the topic of a number of research analyst reports. UBS Group decreased their target price on Teva Pharmaceutical Industries from $30.00 to $27.00 and set a “buy” rating on the stock in a research report on Thursday, January 30th. StockNews.com lowered shares of Teva Pharmaceutical Industries from a “buy” rating to a “hold” rating in a research report on Thursday, March 27th. Bank of America lowered their price objective on shares of Teva Pharmaceutical Industries from $23.00 to $20.00 and set a “buy” rating on the stock in a research note on Thursday, March 6th. Piper Sandler boosted their price target on Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the stock an “overweight” rating in a report on Friday, January 17th. Finally, Barclays decreased their price objective on Teva Pharmaceutical Industries from $28.00 to $26.00 and set an “overweight” rating on the stock in a research note on Thursday, January 30th. Two equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to data from MarketBeat, Teva Pharmaceutical Industries has a consensus rating of “Moderate Buy” and a consensus target price of $23.43.

Teva Pharmaceutical Industries Stock Performance

Teva Pharmaceutical Industries stock opened at $15.39 on Tuesday. The stock has a fifty day moving average price of $17.08 and a 200 day moving average price of $18.11. The company has a current ratio of 0.98, a quick ratio of 0.75 and a debt-to-equity ratio of 2.97. Teva Pharmaceutical Industries Limited has a 52 week low of $12.51 and a 52 week high of $22.80. The firm has a market capitalization of $17.44 billion, a P/E ratio of -10.61, a PEG ratio of 1.44 and a beta of 0.82.

Teva Pharmaceutical Industries (NYSE:TEVA) last announced its quarterly earnings data on Wednesday, January 29th. The company reported $0.70 earnings per share for the quarter, topping the consensus estimate of $0.69 by $0.01. Teva Pharmaceutical Industries had a negative net margin of 9.91% and a positive return on equity of 42.46%. Equities research analysts anticipate that Teva Pharmaceutical Industries Limited will post 2.5 earnings per share for the current year.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.